Emergent Health Corp (EMGE)

[TOUCAN]

Subsidiary IPO on NASDAQ or NYSE/AMEX & dividend

New York, NY / May 18, 2023/ Emergent Health Corp. (OTC PINK: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced that it has executed a Term Sheet and Engagement Letter with Boustead Securities to roll up its subsidiary Evolutionary Biologics and other regenerative medicine and regenerative biologic products companies with NO DILUTION to the Emergent Shareholders with a planned $10 million initial capital raise and public offering and application for listing on NASDAQ or NYSE/AMEX. Emergents subsidiary, Evolutionary Biologics, and the new brand called Maximus Mens Health, along with Juventix Regenerative Medical and Interactive Practice Solutions and Nanosthetic.

Subsequent to the IPO, Emergent plans to distribute the shares received by Emergent from the sale of Evolutionary Biologics as a dividend to its shareholders, pro rata at NO COST to the Emergent Shareholders. Such a dividend would only occur after Emergent files a Registration Statement with the SEC and it is declared effective. Any potential taxable event resulting from such a dividend would be the responsibility of each individual shareholder, and Emergent advises each shareholder to consult with their professional advisors, and makes no representation as to the taxable or nontaxable event. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease.

Jim Morrison, former L'Oral President and Emergents full time CEO stated, Boustead Securities is aworld class financial organization. They approached us to participate in rolling up a series of regenerative biologics into a brand-new IPO. When you look at the effect that this transaction, and the previously announced PharmaZutransaction, will have on EMGE, it's amazing. We see this as a great way to maximize valuation for our Company and take EMGE to the next level.

Executes Term Sheet and Engagement Letter with Boustead Securities to roll up its Subsidiary, Evolutionary Biologics and other regenerative medicine and products companies

https://www.otcmarkets.com/stock/EMGE/news/Emergent-Health-Executes-Term-Sheet-and-Engagement-Letter-with-Boustead-Securities-to-roll-up-its-Subsidiary-Evolutionar?id=401185